By day 40, there were less than 40% of animals left in the group treated with combination therapy (CT26 + 5-FU + IM), while more than 75% survival was observed in the CT26 + 5-FU group and about 60% in the untreated cancer control group (CT26). Here, DDX53 is linked to cancer.